Quantcast
Last updated on April 18, 2014 at 8:37 EDT

Latest Diabetic retinopathy Stories

2012-07-31 22:20:39

GREENWOOD VILLAGE, Colo., Aug. 1, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a clinical stage biopharmaceutical company developing drugs for the treatment of inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction today announced that a pre-IND meeting with the FDA's ophthalmology division of the Center for Drug Evaluation and Research (CDER) took place on July 31(st) 2012 seeking guidance for a clinical trial path...

2012-07-26 02:28:54

ATLANTA, July 26, 2012 /PRNewswire/ -- Alimera Sciences, Inc., (NASDAQ: ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced the Federal Ministry of Health of Germany (Bundesministerium fur Gesundheit, BfArM) has granted marketing authorization to ILUVIEN® for the treatment of vision impairment associated with chronic diabetic macular edema (DME) considered...

2012-07-13 10:37:01

Hypertension frequently coexists in patients with diabetes. A new University of Georgia study shows why the co-morbid conditions can result in impaired vision. "Results showed early signals of cell death in eyes from diabetic animals within the first six weeks of elevated blood pressure. Later, the tiny blood vessels around the optic nerve that nourish the retina and affect visual processing showed signs of decay as early as 10 weeks after diabetic animals develop hypertension," said Azza...

2012-07-11 06:26:25

HONOLULU, July 11, 2012 /PRNewswire/ -- The Retina Institute of Hawaii is one of approximately forty centers participating in the study of an investigational drug for Wet Age-Related Macular Degeneration (AMD), a leading cause of severe vision loss in the elderly. Open since 2001, Retina continues to focus their commitment on finding the best possible future treatments for retinal diseases and providing access to research options. The investigational drug, called AGN-150998, is being...

2012-07-08 22:21:18

GREENWOOD VILLAGE, Colo., July 9, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company developing innovative proprietary drugs for inflammation, eye disease, kidney disease, CNS disease, metabolic disease and male sexual dysfunction and conducting clinical trials on its three lead drugs (Ampion(TM) , Optina(TM) & Zertane(TM)), announced the significant results from their further analysis of its Optina(TM) trial on DME . (Logo:...

2012-06-14 23:01:19

Bernstein Liebhard LLP reports on a new study linking Actos to diabetic macular edema, a serious eye problem. New York, New York (PRWEB) June 14, 2012 Bernstein Liebhard LLP, a New York law firm nationally recognized for its consumer protection and mass tort practices, reports on a June 11, 2012 study that found that diabetes medications such as Actos may cause a serious eye problem called diabetic macular edema.* The study, published in the Archives of Internal Medicine, found that...

2012-06-11 21:53:45

Researchers at Joslin Diabetes Center hope to use experiences of people with long-term type 1 diabetes to benefit others Researchers at Joslin Diabetes Center, supported by JDRF, have completed a study of 158 people who have lived with type 1 diabetes (T1D) for 50 years or more with eye examinations at Joslin over many decades of follow-up, and have concluded that a high proportion of this unique group of patients developed little to no diabetic eye disease over time. The study focuses on...

2012-06-10 22:20:45

GREENWOOD VILLAGE, Colo., June 11, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a clinical stage biopharmaceutical company, whose lead drugs treat inflammatory diseases, including osteoarthritis and complications of Diabetes Mellitus such as diabetic macular edema (and others) announced today that it's CRO has completed analysis of the primary end point in the Optina(TM) clinical trial for DME conducted at St Michael Diabetes Hospital in Toronto Canada. (Logo:...

2012-05-31 02:25:20

GREENWOOD VILLAGE, Colo., May 31, 2012 /PRNewswire/ -- Ampio Pharmaceuticals, Inc. (Nasdaq: AMPE), a biopharmaceutical company conducting clinical trials on its three lead drugs (Ampion(TM), Optina(TM) and Zertane(TM)), licensing distribution of these drugs and developing additional new drugs, today announced that The European Patent Office (EPO) has notified the company that it will grant a patent covering Ampio's Optina(TM)( )product. The patent will protect...

2012-05-16 22:29:41

ACE2, a molecule that has been shown to prevent damage in the heart, is now proving to be protective of the major organs that are often damaged in diabetic patients. Gavin Oudit, a researcher with the Faculty of Medicine & Dentistry, and his colleagues at the University of Florida, found that lab models that lacked ACE2 had worse cardiovascular complications related to diabetes. "We show that if you take ACE2 away, they [lab models of diabetes] do very poorly," said Oudit. "It...